Shionogi's COVID Antiviral Xocova Approved by FDA as Post‑Exposure Preventive for COVID-19 in the U.S. on June 01, 2026 Approved COVID19 (disease) ensitrelvir Injury due to exposure to external cause Post-Exposure Prophylaxis Prophylactic treatment shionogi United States Food and Drug Administration Xocova +